These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


138 related items for PubMed ID: 7598140

  • 1. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.
    Wimalawansa SJ.
    Am J Med; 1995 Jul; 99(1):36-42. PubMed ID: 7598140
    [Abstract] [Full Text] [Related]

  • 2. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ.
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [Abstract] [Full Text] [Related]

  • 3. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB, Becker P.
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
    Cortet B, Béra-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B.
    Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
    Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD.
    Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
    [Abstract] [Full Text] [Related]

  • 8. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwanese postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study.
    Chen M, Chow SN.
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):253-8. PubMed ID: 11531934
    [Abstract] [Full Text] [Related]

  • 9. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
    Hasling C, Charles P, Jensen FT, Mosekilde L.
    Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
    [Abstract] [Full Text] [Related]

  • 10. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
    Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S.
    Osteoporos Int; 1997 Jul; 7(2):133-7. PubMed ID: 9166393
    [Abstract] [Full Text] [Related]

  • 11. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density.
    Miller BE, De Souza MJ, Slade K, Luciano AA.
    Menopause; 2000 Jul; 7(5):318-26. PubMed ID: 10993031
    [Abstract] [Full Text] [Related]

  • 12. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
    Gürlek A, Bayraktar M, Gedik O.
    Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
    [Abstract] [Full Text] [Related]

  • 13. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
    Morishige K, Yamamoto T, Sawada K, Ohmichi M, Tasaka K, Murata Y.
    Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
    [Abstract] [Full Text] [Related]

  • 14. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
    Anderson FH, Francis RM, Bishop JC, Rawlings DJ.
    Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
    [Abstract] [Full Text] [Related]

  • 15. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
    Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett AH, Baylink DJ, Crusan CE, Chines AA.
    J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
    [Abstract] [Full Text] [Related]

  • 16. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I, Herd RJ, Blake GM, Balena R.
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [Abstract] [Full Text] [Related]

  • 17. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
    Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH.
    Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
    [Abstract] [Full Text] [Related]

  • 18. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women.
    Miller PD, Neal BJ, McIntyre DO, Yanover MJ, Anger MS, Kowalski L.
    Osteoporos Int; 1991 Jun; 1(3):171-6. PubMed ID: 1790405
    [Abstract] [Full Text] [Related]

  • 19. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

  • 20. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T, Campbell J, Bryant C, Lynch W.
    Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.